BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26284
Abstract: Patients with hematologic malignancies have an increased risk of severe COVID‐19 infection. Vaccination against COVID‐19 is especially important in these patients, but whether they develop an immune response following vaccination is unknown. We studied serologic… read more here.
Keywords: significantly less; patients hematologic; hematologic malignancies; antibody titers ... See more keywords
Optical genome mapping for structural variation analysis in hematologic malignancies
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26587
Abstract: Optical genome mapping (OGM) is a technology that is rapidly being adopted in clinical genetics laboratories for its ability to detect structural variation (e.g., translocations, inversions, deletions, duplications, etc.) and replace several concurrent standard of… read more here.
Keywords: hematologic malignancies; genome mapping; genome; optical genome ... See more keywords
Meaningful endpoints for therapies approved for hematologic malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30622
Abstract: Overall survival (OS) is considered the gold standard for determining treatment efficacy in oncology trials, but the relation between treatment and OS can be challenging to assess because of long study durations and the impact… read more here.
Keywords: endpoints therapies; approved hematologic; therapies approved; hematologic malignancies ... See more keywords
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34354
Abstract: Patients with hematologic malignancies have impaired humoral immunity secondary to their malignancy and its treatment, placing them at risk of severe coronavirus disease‐19 (COVID‐19) infection and reduced response to vaccination. read more here.
Keywords: hematologic malignancies; vaccination; initial booster; covid ... See more keywords
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3087
Abstract: Circulating tumor DNA (ctDNA) has become the most investigated analyte in blood. It is shed from the tumor into the circulation and represents a subset of the total cell‐free DNA (cfDNA) pool released into the… read more here.
Keywords: cell; dna; ctdna; hematologic malignancies ... See more keywords
Therapy resistance mechanisms in hematological malignancies
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34243
Abstract: Hematologic malignancies are model diseases for understanding neoplastic transformation and serve as prototypes for developing effective therapies. Indeed, the concept of systemic cancer therapy originated in hematologic malignancies and has guided the development of chemotherapy,… read more here.
Keywords: therapy resistance; hematologic malignancies; resistance; treatment ... See more keywords
Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.29769
Abstract: Hematologic malignancies comprise a considerable part of cancers with high mortality at any age. Since the introduction of hematopoietic stem cell transplantation (HSCT), the overall survival of patients dramatically increased. The main goal of HSCT… read more here.
Keywords: hematologic malignancies; physiology; checkpoints hematologic; immune cells ... See more keywords
Association between myelofibrosis and risk of non-hematologic malignancies: a population-based retrospective cohort study
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-03973-z
Abstract: Controversy regarding the risk of non-hematologic malignancies in myelofibrosis patients still exists. We aimed to examine the association between myelofibrosis and non-hematologic malignancies. A cohort of 1,469,790 adults without a diagnosis of myelofibrosis was identified… read more here.
Keywords: non hematologic; myelofibrosis; hematologic malignancies; association ... See more keywords
Factors associated with muscle function in patients with hematologic malignancies undergoing chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-019-04955-2
Abstract: Purpose Muscle dysfunction such as loss of muscle mass and decreased muscle strength is often observed in patients with hematologic malignancies. However, specific factors associated with muscle function have not been identified. The purpose of… read more here.
Keywords: muscle; patients hematologic; hematologic malignancies; factors associated ... See more keywords
Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)
Sign Up to like & getrecommendations! Published in 2019 at "Science China Life Sciences"
DOI: 10.1007/s11427-019-9594-7
Abstract: This study compared G-CSF/ATG and PTCy in myeloablative haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for hematologic malignancies between January 2013 and March 2018 reporting to the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). For each… read more here.
Keywords: group; myeloablative haploidentical; hematologic malignancies; transplantation ... See more keywords
Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Sign Up to like & getrecommendations! Published in 2019 at "Current Oncology Reports"
DOI: 10.1007/s11912-019-0759-5
Abstract: Purpose of ReviewThe purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field.Recent FindingsBispecific antibodies are molecules able… read more here.
Keywords: hematologic malignancies; bispecific antibodies; malignancies best; oncology ... See more keywords